RABS

Barrier Systems for Every Pharmaceutical Process

Tema Sinergie develops custom RABS systems tailored to the specific requirements of the process to be protected, managing every step directly: from preliminary audits to design, sizing, and integration with third-party suppliers.

Each solution is engineered to meet the highest aseptic standards, ensuring ease of cleaning, accessibility, and ergonomics, in full compliance with the most stringent cGMP regulations (Grade A, ISO 5, in Grade B, ISO 7 environments) and major international guidelines. Fully compatible with retrofitting projects on existing facilities.

COMPATIBLE WITH NEW AGLTS 2

Available downloads:
  • Pharma & Biotech Brochure

Are you interested in this product?

A TAILOR-MADE APPROACH

 

All RABS systems developed by Tema Sinergie provide stringent and effective protection for the entire pharmaceutical manufacturing process, dramatically reducing the risk of contamination due to human intervention.

To ensure maximum safety, Tema Sinergie performs an in-depth analysis of the process characteristics and potential criticalities, in order to implement targeted engineering solutions and design systems that maximize production flow reliability.

Every Tema Sinergie RABS system is a fully customized project. Elements such as ventilation, glass surfaces, and localized air intakes are optimized according to the specific process.

 

This tailor-made approach is ideal even for retrofitting applications.

Available downloads:
  • Pharma & Biotech Brochure

Are you interested in this product?

TYPES OF RABS

Thanks to an integrated approach and in-depth knowledge of aseptic processes, Tema Sinergie designs a wide range of RABS systems, meeting all current requirements for aseptic manufacturing.

 

Open RABS (O-RABS)

O-RABS systems feature a direct connection with the surrounding environment. The air flowing through the sterile process area is exhausted directly into the cleanroom.

If equipped with its own ventilation system — including fans, filters, and control units — it is classified as active. If it relies solely on the room’s ventilation system, it is defined as passive.

Closed RABS (C-RABS)

C-RABS systems provide a higher level of protection than O-RABS thanks to a fully enclosed configuration, even though they are not sealed systems.


Air inside a C-RABS is recirculated through its own ventilation system, allowing for more precise and secure airflow control within the process environment.

Existing Facilities Retrofitting & GMP Annex 1

 

  • Thanks to a consolidated design methodology, Tema Sinergie supports customers throughout every phase of production line requalification. 
  • Each project starts with a thorough preliminary analysis of the facility and its processesa critical step to identify issues, define priorities, and configure the most appropriate RABS solution, tailored to the laboratory’s specific needs and production requirements.
  • Our technical team works in close collaboration with the customer to design, install, and qualify RABS systems that effectively requalify existing lines while ensuring full compliance with GMP Annex 1. Learn more

 

 

Contact us for a personalized consultation.

Available downloads:
  • Pharma & Biotech Brochure

Are you interested in this product?

KEY FEATURES

Operational Versatility

Tema Sinergie’s RABS systems offer maximum configuration flexibility and custom technical solutions, ensuring seamless integration with any plant or cleanroom.

ERGONOMIC DESIGN

Optimizing operator workflow is essential to minimize accident risk, reduce unplanned downtime, and uphold high production quality standards. Ergonomic design ensures a safe and comfortable working environment.

REMOTE ASSISTANCE

Through a secure VPN connection, remote access, troubleshooting, software updates, and maintenance interventions can be carried out anytime, anywhere.

ENERGY
SAVING

Low-voltage fans designed with sustainability in mind allow the isolator to maintain low energy consumption throughout its operational life.

SERVICES

 

  • Preliminary analysis and feasibility studies for retrofitting projects
  • Custom engineering consulting and design
  • Technical support for process development
  • Design and construction of full-scale 1:1 mock-ups
  • CFD (Computational Fluid Dynamics) simulations
  • Validation activities and regulatory compliance support
Available downloads:
  • Pharma & Biotech Brochure

Are you interested in this product?

INTEGRATED GLOVE TEST SYSTEM

 
 

I sistemi RABS possono essere equipaggiati con un Sistema integrato di Test Guanti Automatico (AGLTS 2), conforme allo standard internazionale ISO 14644-7 Annex E.5 e alle nuove disposizioni dell’Annex 1, EU Guidelines.

 

Key Features

  • Wireless inductive charging
  • Data transmission via Wi-Fi technology
  • 10” color capacitive touchscreen display
  • Compatible with any type of glove port
  • On-board calibration system
  • Glove life cycle monitoring
  • Easy integration with Active Directory
  • RFID technology
  • Detection of holes as small as 100 µm in diameter

 

Discover all features on:

www.aglts2.com

HUMAN MACHINE INTERFACE

 

RABS systems are controlled by a Siemens S7-1500 PLC and a 12” SIMATIC HMI panel, featuring touchscreen TFT widescreen display and user-friendly graphics.

 

The operator interface, developed by Tema Sinergie, enables simple and intuitive use, including a “one-touch” function and access to saved work programs.

 

The control software is fully compliant with GAMP5 and FDA 21 CFR Part 11 requirements.

 

    Touch panel
    L’interfaccia registra in modo affidabile tutti i dati rilevanti del processo in corso.

    User friendly
    Grafica intuitiva, progettata per facilitare l’operatore.

    Data management
    Flessibilità nella gestione e nell’archiviazione dei dati.

Available downloads:
  • Pharma & Biotech Brochure

Are you interested in this product?

© 2025 TEMA SINERGIE S.p.A
C.F., P.IVA, VATn. IT00970310397
Business Register of Ravenna n. 00970310397  |  R.E.A. 111877
RAEE IT08020000002755
Capital Stock € 2,000,140.08 paid-up